-Reuters Citing U.S. Officials
HC Wainwright & Co. Reiterates Buy on Karuna Therapeutics, Maintains $320 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Karuna Therapeutics (NASDAQ:KRTX) with a Buy and maintains $320 price target.